Kiora Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KPRX research report →
Price Chart
About the company
Kiora Pharmaceuticals, Inc. , a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials.
- CEO
- Brian Strem
- IPO
- 2015
- Employees
- 13
- HQ
- Encinitas, CA, US
Get TickerSpark's AI analysis on KPRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.08M
- P/E
- -1.00
- Fwd P/E
- 1.97
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 0.92
- EV/EBITDA
- -0.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -63.39%
- ROIC
- -53.16%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-24,801-100.2%
- Op Income
- $-9,459,247
- Net Income
- $-10,835,154-401.4%
- EPS
- $-2.64-383.9%
- OCF Growth
- -216.4%
- FCF Growth
- -217.8%
- 52W High
- $2.95
- 52W Low
- $1.76
- 50D MA
- $2.60
- 200D MA
- $2.39
- Beta
- -0.39
- RSI (14)
- 41
- Avg Volume
- 17.04K
No earnings-call transcripts are available for KPRX yet.
- Free Float
- 94.2%
- Shares Outstanding
- 4.43M
- Float Shares
- 4.17M
of shares held by institutions
12 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 10 ETFs
Biggest fund positions in KPRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 26 | Lane Keith J. | other | 55,000 |
| Sep 8, 26 | Lane Keith J. | other | 0 |
| Jul 1, 26 | Tosca Melissa | other | 911 |
| Jul 1, 26 | Strem Brian M. | other | 1,869 |
| Jun 10, 26 | Stengone Carmine N. | other | 25,000 |
| Jun 10, 26 | Shapiro Aron | other | 25,000 |
| Jun 10, 26 | Parsons Erin | other | 25,000 |
| Jun 10, 26 | Hollander David | other | 25,000 |
| Jun 10, 26 | Walters-Hoffert Lisa | other | 25,000 |
| Jun 10, 26 | TYLE PRAVEEN | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KPRX coverage
Recent articles, reports, and earnings notes.
No research on KPRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KPRX report →Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
newsfilecorp.com · Aug 19
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
newsfilecorp.com · Aug 7
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
newsfilecorp.com · Jul 2
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
newsfilecorp.com · Jun 18
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
newsfilecorp.com · May 8
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
newsfilecorp.com · Apr 14
Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)
defenseworld.net · Apr 14
Kiora Pharmaceuticals Announces Management Team Changes
newsfilecorp.com · Apr 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.